Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients

This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizushige, Tomoko, Kobori, Hiroyuki, Hitomi, Hirofumi, Nishijima, Yoko, Tomoda, Fumihiro, Morimoto, Satoshi, Kohno, Masakazu, Nishiyama, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133801/
https://www.ncbi.nlm.nih.gov/pubmed/27801805
http://dx.doi.org/10.3390/ijms17111800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133801/
https://www.ncbi.nlm.nih.gov/pubmed/27801805
http://dx.doi.org/10.3390/ijms17111800

Ejemplares similares